

Alzheimer's Disease (AD)

## A Study of MTAU9937A in Patients With Moderate Alzheimer's Disease

**Trial Status**  
Completed

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT03828747 GN40040

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. There may be up to two study cohorts.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

**NCT03828747 GN40040**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥50 Years & ≤ 85 Years

**Healthy Volunteers**  
No